Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Abroad (travel likely)RecruitingPHASE2

Conditions

Hairy Cell Leukemia · Recurrent Hairy Cell Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

M D Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Farhad Ravandi-Kashani, MD) · fravandi@mdanderson.org · 713-792-7305
Contact: Principal Investigator (Farhad Ravandi-Kashani, MD)

Study leads

Farhad Ravandi-Kashani
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Hairy Cell Leukemia · Recurrent Hairy Cell Leukemia · Refractory Hairy Cell Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States · Columbus, United States

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Hairy Cell Leukemia

Abroad (travel likely)RecruitingPHASE2

Boston, United States · Rochester, United States

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Hairy Cell Leukemia

Abroad (travel likely)RecruitingPHASE2, PHASE3

Ansbach, Germany · Aschaffenburg, Germany

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recurrent Hairy Cell Leukemia · Recurrent Hairy Cell Leukemia Variant

Abroad (travel likely)RecruitingPHASE2

Duarte, United States · Irvine, United States